NCT07572760Recruiting
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are: * Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy? * Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy? Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer. Participants will: * Participate in a supervised exercise program twice a week for 6 months or maintain routine care. * Perform fitness tests and questionnaires about quality of life and mental health. * Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 10 Apr 2024
- Primary completion date
- 10 Nov 2026
- Lead sponsor
- University of Alicante
- Diseases
- Prostate cancer
- NCT number
- NCT07572760
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 10 Apr 2024 to the primary completion date, 10 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior treatment with a triplet regimen that includes chemotherapy.
Other illness
- Evidence of visceral metastatic disease.
- History of pathological fracture.
Who the study is looking for
- Histopathologically confirmed diagnosis of prostate adenocarcinoma.
- Metastatic hormone-sensitive prostate cancer (mHSPC), defined as:
- Presence of metastases at initial diagnosis (synchronous mHSPC), or
- Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC).
- Evidence of progression to castration-resistant prostate cancer (CRPC).
- Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment.
- Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates.
- Presence of metastatic involvement limited to bone and/or lymph nodes.
- Functionally independent in activities of daily living.
Age in the registry: 50 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alicante Coordinator of this site? Confirm its status | San Vicent del Raspeig | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.